13 September 2020 - The Department of Health has once revised the agenda for the upcoming November PBAC meeting without notice. 

The changes are:

• BMS appears to have withdrawn one presentation of ipilimumab (Yervoy) for use in combination with nivolumab and chemotherapy for the first-line treatment of patients with non-small cell lung cancer
• The entry for tofacitinib citrate now indicated there are in fact two submissions; one major and one minor

The URL for the agenda remains unchanged.

Insofar as one of the medicines in the agenda is misspelt, don't be surprised if there isn't another version soon.

Read PBAC agenda